With this in mind, the dose-dependent on-target off-tumour reactivity of ImmTAC-gp100 against skin melanocytes, know to present gp100 peptide, was investigated using primary melanocyte cultures to further inform on the potential therapeutic window for ImmTAC-gp100 in the clinic. Here, PMEL is linked to neoplasm.